The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Therapeutic Recombinant Protein Market Research Report 2025
Synopsis
Therapeutic recombinant proteins are proteins that are produced by recombinant DNA technology and are used as drugs to treat various medical conditions. Recombinant DNA technology involves the use of genetically engineered microorganisms or cells to produce large quantities of a specific protein that has therapeutic potential. Therapeutic recombinant proteins are used to treat a wide range of medical conditions, including cancer, autoimmune diseases, genetic disorders, and infectious diseases. These proteins are designed to mimic the natural proteins in the body that regulate various biological processes. They are often administered by injection, and their effectiveness depends on the specific protein and the medical condition being treated.
Global Therapeutic Recombinant Protein market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Therapeutic Recombinant Protein market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Therapeutic Recombinant Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abcam
HALIX
Avantor
Miltenyi Biotec
Thermo Fisher Scientific
Bio-Techne Corporation
Merck
ACROBiosystems
Abnova
Eurogentec (Kaneka Corporation)
Cytiva (Danaher )
Reprocell
GenScript
BPS Bioscience
Sino Biological
Segment by Type
Hormones
Blood Clotting Factors
Cytokines
Enzymes
Fusion Proteins
Others
Segment by Application
Pharmaceutical Company
Research Institute
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Therapeutic Recombinant Protein report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Therapeutic recombinant proteins are proteins that are produced by recombinant DNA technology and are used as drugs to treat various medical conditions. Recombinant DNA technology involves the use of genetically engineered microorganisms or cells to produce large quantities of a specific protein that has therapeutic potential. Therapeutic recombinant proteins are used to treat a wide range of medical conditions, including cancer, autoimmune diseases, genetic disorders, and infectious diseases. These proteins are designed to mimic the natural proteins in the body that regulate various biological processes. They are often administered by injection, and their effectiveness depends on the specific protein and the medical condition being treated.
Global Therapeutic Recombinant Protein market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Therapeutic Recombinant Protein market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Therapeutic Recombinant Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abcam
HALIX
Avantor
Miltenyi Biotec
Thermo Fisher Scientific
Bio-Techne Corporation
Merck
ACROBiosystems
Abnova
Eurogentec (Kaneka Corporation)
Cytiva (Danaher )
Reprocell
GenScript
BPS Bioscience
Sino Biological
Segment by Type
Hormones
Blood Clotting Factors
Cytokines
Enzymes
Fusion Proteins
Others
Segment by Application
Pharmaceutical Company
Research Institute
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Therapeutic Recombinant Protein report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Therapeutic Recombinant Protein Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hormones
1.2.3 Blood Clotting Factors
1.2.4 Cytokines
1.2.5 Enzymes
1.2.6 Fusion Proteins
1.2.7 Others
1.3 Market by Application
1.3.1 Global Therapeutic Recombinant Protein Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Research Institute
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Therapeutic Recombinant Protein Market Perspective (2018-2029)
2.2 Therapeutic Recombinant Protein Growth Trends by Region
2.2.1 Global Therapeutic Recombinant Protein Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Therapeutic Recombinant Protein Historic Market Size by Region (2018-2023)
2.2.3 Therapeutic Recombinant Protein Forecasted Market Size by Region (2024-2029)
2.3 Therapeutic Recombinant Protein Market Dynamics
2.3.1 Therapeutic Recombinant Protein Industry Trends
2.3.2 Therapeutic Recombinant Protein Market Drivers
2.3.3 Therapeutic Recombinant Protein Market Challenges
2.3.4 Therapeutic Recombinant Protein Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Therapeutic Recombinant Protein Players by Revenue
3.1.1 Global Top Therapeutic Recombinant Protein Players by Revenue (2018-2023)
3.1.2 Global Therapeutic Recombinant Protein Revenue Market Share by Players (2018-2023)
3.2 Global Therapeutic Recombinant Protein Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Therapeutic Recombinant Protein Revenue
3.4 Global Therapeutic Recombinant Protein Market Concentration Ratio
3.4.1 Global Therapeutic Recombinant Protein Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Therapeutic Recombinant Protein Revenue in 2022
3.5 Therapeutic Recombinant Protein Key Players Head office and Area Served
3.6 Key Players Therapeutic Recombinant Protein Product Solution and Service
3.7 Date of Enter into Therapeutic Recombinant Protein Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Therapeutic Recombinant Protein Breakdown Data by Type
4.1 Global Therapeutic Recombinant Protein Historic Market Size by Type (2018-2023)
4.2 Global Therapeutic Recombinant Protein Forecasted Market Size by Type (2024-2029)
5 Therapeutic Recombinant Protein Breakdown Data by Application
5.1 Global Therapeutic Recombinant Protein Historic Market Size by Application (2018-2023)
5.2 Global Therapeutic Recombinant Protein Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Therapeutic Recombinant Protein Market Size (2018-2029)
6.2 North America Therapeutic Recombinant Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Therapeutic Recombinant Protein Market Size by Country (2018-2023)
6.4 North America Therapeutic Recombinant Protein Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Therapeutic Recombinant Protein Market Size (2018-2029)
7.2 Europe Therapeutic Recombinant Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Therapeutic Recombinant Protein Market Size by Country (2018-2023)
7.4 Europe Therapeutic Recombinant Protein Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Therapeutic Recombinant Protein Market Size (2018-2029)
8.2 Asia-Pacific Therapeutic Recombinant Protein Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Therapeutic Recombinant Protein Market Size by Region (2018-2023)
8.4 Asia-Pacific Therapeutic Recombinant Protein Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Therapeutic Recombinant Protein Market Size (2018-2029)
9.2 Latin America Therapeutic Recombinant Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Therapeutic Recombinant Protein Market Size by Country (2018-2023)
9.4 Latin America Therapeutic Recombinant Protein Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Therapeutic Recombinant Protein Market Size (2018-2029)
10.2 Middle East & Africa Therapeutic Recombinant Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Therapeutic Recombinant Protein Market Size by Country (2018-2023)
10.4 Middle East & Africa Therapeutic Recombinant Protein Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abcam
11.1.1 Abcam Company Detail
11.1.2 Abcam Business Overview
11.1.3 Abcam Therapeutic Recombinant Protein Introduction
11.1.4 Abcam Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.1.5 Abcam Recent Development
11.2 HALIX
11.2.1 HALIX Company Detail
11.2.2 HALIX Business Overview
11.2.3 HALIX Therapeutic Recombinant Protein Introduction
11.2.4 HALIX Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.2.5 HALIX Recent Development
11.3 Avantor
11.3.1 Avantor Company Detail
11.3.2 Avantor Business Overview
11.3.3 Avantor Therapeutic Recombinant Protein Introduction
11.3.4 Avantor Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.3.5 Avantor Recent Development
11.4 Miltenyi Biotec
11.4.1 Miltenyi Biotec Company Detail
11.4.2 Miltenyi Biotec Business Overview
11.4.3 Miltenyi Biotec Therapeutic Recombinant Protein Introduction
11.4.4 Miltenyi Biotec Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.4.5 Miltenyi Biotec Recent Development
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Company Detail
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Therapeutic Recombinant Protein Introduction
11.5.4 Thermo Fisher Scientific Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.5.5 Thermo Fisher Scientific Recent Development
11.6 Bio-Techne Corporation
11.6.1 Bio-Techne Corporation Company Detail
11.6.2 Bio-Techne Corporation Business Overview
11.6.3 Bio-Techne Corporation Therapeutic Recombinant Protein Introduction
11.6.4 Bio-Techne Corporation Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.6.5 Bio-Techne Corporation Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Therapeutic Recombinant Protein Introduction
11.7.4 Merck Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.7.5 Merck Recent Development
11.8 ACROBiosystems
11.8.1 ACROBiosystems Company Detail
11.8.2 ACROBiosystems Business Overview
11.8.3 ACROBiosystems Therapeutic Recombinant Protein Introduction
11.8.4 ACROBiosystems Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.8.5 ACROBiosystems Recent Development
11.9 Abnova
11.9.1 Abnova Company Detail
11.9.2 Abnova Business Overview
11.9.3 Abnova Therapeutic Recombinant Protein Introduction
11.9.4 Abnova Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.9.5 Abnova Recent Development
11.10 Eurogentec (Kaneka Corporation)
11.10.1 Eurogentec (Kaneka Corporation) Company Detail
11.10.2 Eurogentec (Kaneka Corporation) Business Overview
11.10.3 Eurogentec (Kaneka Corporation) Therapeutic Recombinant Protein Introduction
11.10.4 Eurogentec (Kaneka Corporation) Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.10.5 Eurogentec (Kaneka Corporation) Recent Development
11.11 Cytiva (Danaher )
11.11.1 Cytiva (Danaher ) Company Detail
11.11.2 Cytiva (Danaher ) Business Overview
11.11.3 Cytiva (Danaher ) Therapeutic Recombinant Protein Introduction
11.11.4 Cytiva (Danaher ) Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.11.5 Cytiva (Danaher ) Recent Development
11.12 Reprocell
11.12.1 Reprocell Company Detail
11.12.2 Reprocell Business Overview
11.12.3 Reprocell Therapeutic Recombinant Protein Introduction
11.12.4 Reprocell Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.12.5 Reprocell Recent Development
11.13 GenScript
11.13.1 GenScript Company Detail
11.13.2 GenScript Business Overview
11.13.3 GenScript Therapeutic Recombinant Protein Introduction
11.13.4 GenScript Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.13.5 GenScript Recent Development
11.14 BPS Bioscience
11.14.1 BPS Bioscience Company Detail
11.14.2 BPS Bioscience Business Overview
11.14.3 BPS Bioscience Therapeutic Recombinant Protein Introduction
11.14.4 BPS Bioscience Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.14.5 BPS Bioscience Recent Development
11.15 Sino Biological
11.15.1 Sino Biological Company Detail
11.15.2 Sino Biological Business Overview
11.15.3 Sino Biological Therapeutic Recombinant Protein Introduction
11.15.4 Sino Biological Revenue in Therapeutic Recombinant Protein Business (2018-2023)
11.15.5 Sino Biological Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
